These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35271262)

  • 1. Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4.
    Shao M; Chen X; Yang F; Song X; Zhou Y; Lin Q; Fu Y; Ortega R; Lin X; Tu Z; Patterson AV; Smaill JB; Chen Y; Lu X
    J Med Chem; 2022 Mar; 65(6):5113-5133. PubMed ID: 35271262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of indazole derivatives as selective covalent inhibitors of FGFR4 in wild-type and gatekeeper mutants.
    Yang Y; He X; Li Z; Ran K; Wang N; Zhao L; Liu Z; Zeng J; Chang B; Feng Q; Zhang Q; Yu L
    Eur J Med Chem; 2023 Oct; 258():115628. PubMed ID: 37437349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2-
    Yang F; Chen X; Song X; Ortega R; Lin X; Deng W; Guo J; Tu Z; Patterson AV; Smaill JB; Chen Y; Lu X
    J Med Chem; 2022 Nov; 65(21):14809-14831. PubMed ID: 36278929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma.
    Oh H; Kim J; Jung SH; Ha TH; Ahn YG; Nam G; Moon K; Singh P; Kim IS
    J Med Chem; 2024 May; 67(10):8445-8459. PubMed ID: 38706130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma.
    Tao Z; Cui Y; Xu X; Han T
    Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2208844119. PubMed ID: 36179047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
    Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
    Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and anticancer evaluation of arylurea derivatives as potent and selective type II irreversible covalent FGFR4 inhibitors.
    Wang M; Lan L; Wang YW; Zhang JY; Shi L; Sun LP
    Bioorg Med Chem; 2023 May; 87():117298. PubMed ID: 37196426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
    Hatlen MA; Schmidt-Kittler O; Sherwin CA; Rozsahegyi E; Rubin N; Sheets MP; Kim JL; Miduturu C; Bifulco N; Brooijmans N; Shi H; Guzi T; Boral A; Lengauer C; Dorsch M; Kim RD; Kang YK; Wolf BB; Hoeflich KP
    Cancer Discov; 2019 Dec; 9(12):1686-1695. PubMed ID: 31575540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.
    Lu X; Chen H; Patterson AV; Smaill JB; Ding K
    J Med Chem; 2019 Mar; 62(6):2905-2915. PubMed ID: 30403487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.
    Kanzaki H; Chiba T; Ao J; Koroki K; Kanayama K; Maruta S; Maeda T; Kusakabe Y; Kobayashi K; Kanogawa N; Kiyono S; Nakamura M; Kondo T; Saito T; Nakagawa R; Ogasawara S; Suzuki E; Ooka Y; Muroyama R; Nakamoto S; Yasui S; Tawada A; Arai M; Kanda T; Maruyama H; Mimura N; Kato J; Zen Y; Ohtsuka M; Iwama A; Kato N
    Sci Rep; 2021 Mar; 11(1):5303. PubMed ID: 33674622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 1,6-Naphthyridin-2(1
    Zhang X; Wang Y; Ji J; Si D; Bao X; Yu Z; Zhu Y; Zhao L; Li W; Liu J
    J Med Chem; 2022 Jun; 65(11):7595-7618. PubMed ID: 35635004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
    Chen X; Liu Y; Zhang L; Chen D; Dong Z; Zhao C; Liu Z; Xia Q; Wu J; Chen Y; Zheng X; Cai Y
    Eur J Med Chem; 2021 Mar; 214():113219. PubMed ID: 33618175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Novel 7-Azaindole Derivatives as Selective Covalent Fibroblast Growth Factor Receptor 4 Inhibitors for the Treatment of Hepatocellular Carcinoma.
    Zhong Z; Shi L; Fu T; Huang J; Pan Z
    J Med Chem; 2022 May; 65(10):7278-7295. PubMed ID: 35549181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4.
    Chen X; Li H; Lin Q; Dai S; Qu L; Guo M; Zhang L; Liao J; Wei H; Xu G; Jiang L; Chen Y
    Eur J Med Chem; 2024 Mar; 268():116281. PubMed ID: 38432058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 2-Amino-7-sulfonyl-7
    Xie W; Yang S; Liang L; Wang M; Zuo W; Lei Y; Zhang Y; Tang W; Lu T; Chen Y; Jiang Y
    J Med Chem; 2022 Dec; 65(24):16570-16588. PubMed ID: 36480917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.
    Joshi JJ; Coffey H; Corcoran E; Tsai J; Huang CL; Ichikawa K; Prajapati S; Hao MH; Bailey S; Wu J; Rimkunas V; Karr C; Subramanian V; Kumar P; MacKenzie C; Hurley R; Satoh T; Yu K; Park E; Rioux N; Kim A; Lai WG; Yu L; Zhu P; Buonamici S; Larsen N; Fekkes P; Wang J; Warmuth M; Reynolds DJ; Smith PG; Selvaraj A
    Cancer Res; 2017 Dec; 77(24):6999-7013. PubMed ID: 29247039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis, and Biological Evaluation of 2-Formyl Tetrahydronaphthyridine Urea Derivatives as New Selective Covalently Reversible FGFR4 Inhibitors.
    Zhang Z; Li J; Chen H; Huang J; Song X; Tu ZC; Zhang Z; Peng L; Zhou Y; Ding K
    J Med Chem; 2022 Feb; 65(4):3249-3265. PubMed ID: 35119278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrrolo[2,3-b]pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma.
    Jin Q; Zhang D; Gao M; Jiang C; Zhang J
    Bioorg Med Chem; 2021 Jan; 29():115862. PubMed ID: 33218898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.
    Weiss A; Adler F; Buhles A; Stamm C; Fairhurst RA; Kiffe M; Sterker D; Centeleghe M; Wartmann M; Kinyamu-Akunda J; Schadt HS; Couttet P; Wolf A; Wang Y; Barzaghi-Rinaudo P; Murakami M; Kauffmann A; Knoepfel T; Buschmann N; Leblanc C; Mah R; Furet P; Blank J; Hofmann F; Sellers WR; Graus Porta D
    Mol Cancer Ther; 2019 Dec; 18(12):2194-2206. PubMed ID: 31409633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential.
    Xie H; Alem Glison DM; Kim RD
    Expert Opin Investig Drugs; 2022 Apr; 31(4):393-400. PubMed ID: 34913780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.